Payment overview · 2025
General Payments
$1,999.36
45 reported records · 15 companies
Healthcare provider profile · identity verified
Georges A Ghacibeh, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Epilepsy · HACKENSACK, NJ · NPI 1851331680
Verified facts
What the public records show
CMS Open Payments records show Georges A Ghacibeh, M.D. received $1,999.36 in general payments during 2025 across 45 reported records.
UCB, Inc. accounted for 54.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Lumryz.
Avadel CNS Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMRYZ as an associated drug or biological on 11767 records involving 3739 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lumryz by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $1,088.76 | 54.5% | 9 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $327.75 | 16.4% | 11 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $161.46 | 8.1% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $107.59 | 5.4% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$69.83 | 3.5% | 4 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.56 | 2.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.24 | 1.7% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$33.36 | 1.7% | 2 | 2025 |
| Otter Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $28.53 | 1.4% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.15 | 1.4% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $17.94 | 0.9% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.97 | 0.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.20 | 0.8% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $15.12 | 0.8% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $14.90 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $994.37 | 43 |
| Consulting Fee | $950.00 | 1 |
| Education | $54.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $327.75 | 11 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $161.46 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $55.73 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $52.60 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $39.56 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $36.39 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $34.24 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $33.67 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $33.36 | 2 | 2025 |
Source payment records
|
|||||
| SYMPAZAN Normalized: sympazan |
Drug | Otter Pharmaceuticals, LLC | $28.53 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $28.15 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $12.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LUMRYZ lumryz |
2025 | Lumryz | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Avadel CNS Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | LUMRYZ open payments reported associated product |
CMS Open Payments — General Payments 11767 supporting records · 3739 recipient NPIs · example record 1208530440 |
Lumryz · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lamotrigine | Lamotrigine | 125 | 25 |
| Clonazepam | Clonazepam | 94 | 15 |
| Levetiracetam | Levetiracetam | 90 | 21 |
| Divalproex Sodium | Divalproex Sodium | 79 | suppressed |
| Lacosamide | Lacosamide | 73 | 15 |
| Mirtazapine | Mirtazapine | 67 | 17 |
| Clobazam | Clobazam | 65 | 11 |
| Xcopri | Cenobamate | 65 | suppressed |
| Briviact | Brivaracetam | 61 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 59 | 15 |
| Topiramate | Topiramate | 58 | 11 |
| Pregabalin | Pregabalin | 55 | 19 |
| Sertraline Hcl | Sertraline Hcl | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Gabapentin | Gabapentin | 47 | 19 |
| Diazepam | Diazepam | 41 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 39 | suppressed |
| Zonisamide | Zonisamide | 37 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Lamictal | Lamotrigine | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Galantamine Er | Galantamine Hbr | 28 | suppressed |
| Banzel | Rufinamide | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Modafinil | Modafinil | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Lyrica | Pregabalin | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Lumryz | Sodium Oxybate | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Vimpat | Lacosamide | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Lamotrigine Er | Lamotrigine | 17 | suppressed |
| Onfi | Clobazam | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,999.36 · 45 records | UCB, Inc. | Bimzelx, Briviact, Dyanavel XR, Fintepla, GOMEKLI, INSPIRE, KESIMPTA, LUMRYZ, Motpoly XR, Nayzilam, QULIPTA, Qelbree, SYMPAZAN, UBRELVY, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, WAKIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Avadel CNS Pharmaceuticals, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error